Use of a competitive probe in assay design for genotyping of the UGT1A1*28 microsatellite polymorphism by the smart amplification process

BioTechniques

Volumn 43, Issue 4, 2007, Pages 479-484

  Watanabe, Jun ^a,b,e   Mitani, Yasumasa ^a,c,d   Kawai, Yuki ^a,c   Kikuchi, Takeshi ^a,c   Kogo, Yasushi ^a,c   Oguchi Katayama, Atsuko ^a   Kanamori, Hajime ^a,c   Usui, Kengo ^a   Itoh, Masayoshi ^a   Cizdziel, Paul E ^a   Lezhava, Alexander ^a   Tatsumi, Kenji ^a,b   Ichikawa, Yasushi ^b   Togo, Shinji ^b   Shimada, Hiroshi ^b   Hayashizaki, Yoshihide ^a,b  

^a RIKEN   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c KK DNAFORM   (Japan)

^d RIKEN YOKOHAMA INSTITUTE   (Japan)

^e YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; GENETIC ENGINEERING; REACTION KINETICS;

GENETIC VARIATIONS; GENOTYPING; MICROSATELLITES;

POLYMORPHISM;

GENOMIC DNA; MICROSATELLITE DNA; PRIMER DNA; PROTEIN MUTS;

ALLELE; ARTICLE; ASSAY; BLOOD SAMPLING; COMPETITIVE PROBE; DNA POLYMORPHISM; GENE AMPLIFICATION; GENE PROBE; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; REACTION ANALYSIS; REACTION TIME; SEQUENCE ANALYSIS; THERMUS AQUATICUS; TIME;

BIOLOGICAL ASSAY; DNA PROBES; GENOTYPE; GLUCURONOSYLTRANSFERASE; MICROSATELLITE REPEATS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

THERMUS AQUATICUS;

EID: 35748950424     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/000112563     Document Type: Article

References (23)

1. Nagasubramanian, R., F. Innocenti, and M.J. Ratain. 2003. Pharmacogenetics in cancer treatment. Annu. Rev. Med. 54:437-452.
2. Mitani, Y., A. Lezhava, Y. Kawai, T. Kikuchi, A. Oguchi-Katayama, Y. Kogo, M. Itoh, T. Miyagi, et al. 2007. Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nat. Methods 4:257-262.
3. Takakura, H., K. Hoshi, Y. Mitani, K. Tatsumi, N. Momiyama, Y. Ichikawa, S. Togo, T. Miyagi, et al. Use of the SMart-Amplification Process for rapid detection of EGFR mutations in lung cancer. Clin. Cancer Res. (In press).
4. Hasegawa, Y., Y. Ando, M. Ando, N. Hashimoto, K. Imaizumi, and K. Shimokata. 2006. Pharmacogenetic approach for cancer treatment-tailored medicine in practice. Ann. N. Y. Acad. Sci. 1086:223-232.
5. Park, J.H., I.J. Kim, H.C. Kang, Y. Shin, H.W. Park, S.G. Jang, J.L. Ku, S.B. Lim, et al. 2004. Oligonucleotide microarray-based mutation detection of the K-ras gene in colorectal cancers with use of competitive DNA hybridization. Clin. Chem. 50:1688-1691.
6. Parsons, B.L., P.B. McKinzie, and R.H. Heflich. 2005. Allele-specific competitive blocker-PCR detection of rare base substitution. Methods Mol. Biol. 297:235-245.
7. Gibbs, R.A., P.N. Nguyen, and C.T. Caskey. 1989. Detection of single DNA base differences by competitive oligonucleotide priming. Nucleic Acids Res. 77:2437-2448.
8. Monaghan, G., M. Ryan, R. Seddon, R. Hume, and B. Burchell. 1996. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347:578-581.
9. Ando, Y. and Y. Hasegawa. 2005. Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab. Rev. 37:565-574.
10. Ando, Y., H. Saka, M. Ando, T. Sawa, K. Muro, H. Ueoka, A. Yokoyama, S. Saitoh, et al. 2000. Polymorphisms of UDPglucuronosyltransferase gene and irinotecan adverse reactions: a pharmacogenetic analysis. Cancer Res. 60:6921-6926.
11. Kyger, E.M., M.D. Krevolin, and M.J. Powell. 1998. Detection of the hereditary hemochromatosis gene mutation by real-time fluorescence polymerase chain reaction and peptide nucleic acid clamping. Anal. Biochem. 260:142-148.
12. Braasch, D.A. and D.R. Corey. 2001. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol. 8:1-7.
13. Rouits, E., M. Boisdron-Celle, A. Dumont, O. Guerin, A. Morel, and E. Gamelin. 2004. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10:5151-5159.
14. Iyer, L., S. Das, L. Janisch, M. Wen, J. Ramirez, T. Karrison, G.F. Fleming, E.E. Vokes, et al. 2002. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and adverse reactions. Pharmacogenomics J. 2:43-47.
15. Innocenti, F., S.D. Undevia, L. Iyer, P.X. Chen, S. Das, M. Kocherginsky, T. Karrison, L. Janisch, et al. 2004. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22:1382-1388.
16. Marcuello, E., A. Altes, A. Menoyo, E. Del Rio, M. Gomez-Pardo, and M. Baiget. 2004. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91:678-682.
17. Kitagawa, C., M. Ando, Y. Ando, Y. Sekido, K. Wakai, K. Imaizumi, K. Shimokata, and Y. Hasegawa. 2005. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDPglucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet. Genom. 15:35-41.
18. Beutler, E., T. Gelbart, and A. Demina. 1998. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA 95:8170-8174.
19. Innocenti, F., C. Grimsley, S. Das, J. Ramirez, C. Cheng, H. Kuttab-Boulos, M.J. Ratain, and A. Di Rienzo. 2002. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733.
20. Premawardhena, A., C.A. Fisher, Y.T. Liu, I.C. Verma, S. de Silva, M. Arambepola, J.B. Clegg, and D.J. Weatherall. 2003. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol. Dis. 31:98-101.
21. Sai, K., M. Saeki, Y. Saito, S. Ozawa, N. Katori, H. Jinno, R. Hasegawa, N. Kaniwa, et al. 2004. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75:501-515.
22. Sugatani, J., K. Yamakawa, K. Yoshinari, T. Machida, H. Takagi, M. Mori, S. Kakizaki, T. Sueyoshi, et al. 2002. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun. 292:492-497.
23. Hasegawa, Y., T. Sarashina, M. Ando, C. Kitagawa, A. Mori, M. Yoneyama, Y. Ando, and K. Shimokata. 2004. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin. Chem. 50:1479-1480.